• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 520634 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419022168 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419022168 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Biogen Idec (BIIB) Approaches New Downside Target of $198.55

Published on Thu, 06/20/2013 - 13:04
By Adrienne Chilton

Shares of Biogen Idec (NASDAQ:BIIB) opened today below their pivot of $206.22 and have already reached the first level of support at $201.17. Should the shares continue to fall, the support pivots of $198.55 and $190.88 will be of interest.

Biogen Idec share prices have moved between a 52-week high of $242.64 and a 52-week low of $134.00 and are now trading 50% above that low price at $200.55 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.5% while the 50-day MA has advanced 0.4%.

Potential upside of 11.1% exists for Biogen Idec, based on a current level of $200.55 and analysts' average consensus price target of $222.86. The stock should find resistance at its 50-day moving average (MA) of $217.64, as well as support at its 200-day MA of $171.25.

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of State Street Rise Above Previo...

State Street (NYSE:STT) traded today at a new 52-week high of $80.26. Approximately 2 ...

Shares of SunTrust Banks Rise Above Prev...

SunTrust Banks (NYSE:STI) traded today at a new 52-week high of $42.10. So far today a ...

Shares of Stratasys Fall Below Previous ...

Stratasys (NASDAQ:SSYS) traded at a new 52-week low today of $76.60. Approximately 1.5 ...

Watch for Continued Gains in Shares of S...

Shares of Stericycle (NASDAQ:SRCL) traded at a new 52-week high today of $133.63. So f ...

Shares of Spartan Stores Rise to a New 5...

Spartan Stores (NASDAQ:SPTN) traded at a new 52-week high today of $26.17. Approximate ...

Shares of Snap-On Have Risen Above Previ...

Shares of Snap-On (NYSE:SNA) traded at a new 52-week high today of $137.83. So far tod ...

Shares of Super Micro Computer Have Rise...

Shares of Super Micro Computer (NASDAQ:SMCI) traded at a new 52-week high today of $35. ...

Shares of Skilled Healthcare Have Risen ...

Skilled Healthcare (NYSE:SKH) traded at a new 52-week high today of $8.10. This new hi ...